Does sacubitril-valsartan reduce serum uric acid and improve outcomes in patients with heart failure with preserved ejection fraction compared with valsartan?
In patients with HFpEF, sacubitril-valsartan lowers serum uric acid levels compared to valsartan, a reduction that correlates with improved cardiovascular outcomes.
Serum uric acid independently predicted adverse outcomes in HFpEF. Sacubitril-valsartan reduced SUA and the initiation of related therapy compared with valsartan. Reductions in SUA were associated with improved outcomes.
Selvaraj et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: